Aytu Biopharma (AYTU) Short term Debt (2016 - 2026)

Aytu Biopharma (AYTU) has reported Short term Debt for 11 consecutive years, with $10.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Short term Debt rose 3.82% year-over-year to $10.4 million in Q1 2026; TTM through Mar 2026 was $10.4 million, a 3.82% increase from a year earlier, with the FY2025 full-year figure at $9.1 million, up 278.41% from the prior year.
• Short term Debt was $10.4 million for Q1 2026 at Aytu Biopharma, up from $9.1 million in the prior quarter.
• Over five years, Short term Debt peaked at $15.1 million in Q1 2024 and troughed at $1.0 million in Q4 2023.
• A 5-year average of $6.8 million and a median of $7.4 million in 2022 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt surged 464.17% in 2022 and tumbled 86.19% in 2023, its largest moves.
• Over 5 years, Short term Debt stood at $7.4 million in 2022, then slumped by 86.19% to $1.0 million in 2023, then surged by 291.03% to $4.0 million in 2024, then soared by 126.2% to $9.1 million in 2025, then advanced by 14.72% to $10.4 million in 2026.
• The last three Short term Debt figures came in at $10.4 million (Q1 2026), $9.1 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.